COMMUNIQUÉS West-GlobeNewswire

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
09/10/2025
Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysis Over 100 clinical sites across 24 countries now [...]
CDT Equity Inc. Announces Reverse Stock Split
09/10/2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-8 reverse stock split of [...]
Series A Round Valuation: ¥9 Billion: MEDIROM MOTHER Labs Inc. Decides to Make an Investment from Internal Investors
09/10/2025
TOKYO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Yoshio Uekusa; hereinafter “MOTHER Labs”), a subsidiary of MEDIROM Healthcare Technologies Inc. ( [...]
Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy
09/10/2025
KNOXVILLE, Tenn., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of independent preclinical research by Aru Narendran, [...]
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
09/10/2025
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT [...]
Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting, October 18-21 in Orlando
09/10/2025
Results from the study of oral gildeuretinol in moderate Stargardt disease to be presented as late-breaker during Retina Subspecialty Day CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc [...]
Applications Now Open for Fall 2025 First Practice Fund Scholarship
09/10/2025
ST. LOUIS and HINTON, West Virginia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- PracticeLink , the nation’s most trusted physician recruitment resource and home of the most widely used online physician job board, is proud to [...]
Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer
09/10/2025
Pioneering Evidence-Based AI Innovation in Personalized Wellness and Health Research VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY [...]
Toro Neurovascular and Kaneka Announce Exclusive U.S. Distribution Partnership
09/10/2025
Partnership to Enable U.S. Access to Toro’s Novel Neurovascular Catheter Portfolio Pending Regulatory Approval IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Toro Neurovascular, a company pioneering advanced catheter [...]
Optime Care Terminates Distributor Agreement for Korlym® (mifepristone)
09/10/2025
ST. LOUIS, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Following 10+ years of service to Cushing's syndrome patients, Optime Care , a national specialty pharmacy, distribution and patient management organization maximizing [...]
Triumph Steps Launches CLE-Eligible Mental Fitness Program for Lawyers
09/10/2025
Program Aligns with World Mental Health Day, Offering Attorneys a Path to Wellness, Ethics, and Emotional Resilience Miami, Florida, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Triumph Steps , a leading provider of emotional [...]
Foundation Health Secures $20M Series A to Scale AI-Powered Infrastructure for Pharmacy Operations, Care Coordination, and Direct-to-Patient Delivery
09/10/2025
Funding Supports Expansion of PAIGE AI Pharmacist Assistant, Driving Intelligent Automation for Prior Authorizations and Patient Communication Comprehensive Platform Reduces Manual Pharmacy Workflows by Up to 75% While [...]
Legend Senior Living® Grows Florida Footprint With Renaissance of North Tampa
09/10/2025
WICHITA, Kan., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Legend Senior Living®, a nationally recognized senior living provider based in Wichita, KS, has announced the management of Renaissance North Tampa, expanding its Florida [...]
Children's National Hospital receives $8 million grant from Gilbert Family Foundation to advance neurofibromatosis research
09/10/2025
The investment deepens a partnership to transform care for one of the most common genetic conditions in children Washington, DC, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Children’s National Hospital and the Gilbert Family [...]
Safety Shot, Inc. to Become Bonk, Inc., to Trade on Nasdaq Under New Ticker Symbol “BNKK”
09/10/2025
Rebranding Solidifies Company’s Full Strategic Transformation into the Premier Public Vehicle for the BONK Ecosystem SCOTTSDALE, AZ, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the “Company”) [...]
Doheny Eye Institute Announces Upcoming Presentations at the American Academy of Ophthalmology 2025 Annual Meeting
09/10/2025
Doheny-UCLA clinician-scientists selected to deliver more than 25 presentations and talks PASADENA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Doheny Eye Institute , one of the nation’s leading vision research [...]
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
09/10/2025
Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a [...]
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
09/10/2025
MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
ABLi Therapeutics Reports Final Results from the Phase 2 ‘201 Trial’ Evaluating Risvodetinib for the Treatment of Parkinson’s Disease
09/10/2025
Risvodetinib demonstrated to be safe and well-tolerated with preliminary clinical benefits Risvodetinib demonstrated to be the first treatment to reduce alpha-synuclein pathology, widely recognized as the underlying [...]

Pages